ReviewCurrent pain and headache reports2021
Headache as a Symptom of COVID-19: Narrative Review of 1-Year Research.
Review in Current pain and headache reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Cytokines in primary headache disorders: a systematic review and meta-analysis.The journal of headache and pain · 2023Pooled it
- Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis.The journal of headache and pain · 2022Pooled it
- Review
- Acute and long-term effects of COVID-19 on brain and mental health: A narrative review.Brain, behavior, and immunity · 2025Review
- The Impact of COVID-19 on Migraine: The Patients' Perspective.Life (Basel, Switzerland) · 2024Article
- Prevalence and Risk Factors of Headache Associated with COVID-19.Journal of clinical medicine · 2024Article
- Satellite Glial Cells in Human Disease.Cells · 2024Review
- History of Migraine and Risk of COVID-19: A Cohort Study.The American journal of medicine · 2023Article
- NEURO-COVAX: An Italian Population-Based Study of Neurological Complications after COVID-19 Vaccinations.Vaccines · 2023Article
- Patterns of Opioid and Non-Opioid Analgesic Consumption in Patients with Post-COVID-19 Conditions.Journal of clinical medicine · 2023Article
- Prognostic Role of Clinical Features of Moderate Forms of COVID-19 Requiring Hospitalization.Journal of personalized medicine · 2023Article
- Importance of Magnesium Status in COVID-19.Biology · 2023Review
- Pain Management in the Post-COVID Era-An Update: A Narrative Review.Pain and therapy · 2023Review
- New-onset headache following COVID-19: An Italian multicentre case series.Journal of the neurological sciences · 2023Article
- COVID-19 neuropsychiatric repercussions: Current evidence on the subject.World journal of methodology · 2022Review
- Long COVID headache.The journal of headache and pain · 2022Review
- Assessment of Smell and Taste Disturbances among COVID-19 Convalescent Patients: A Cross-Sectional Study in Armenia.Journal of clinical medicine · 2022Article
- Brain Imaging Changes in Patients Recovered From COVID-19: A Narrative Review.Frontiers in neuroscience · 2022Article
- Post COVID-19 vaccination headache: A clinical and epidemiological evaluation.Frontiers in pain research (Lausanne, Switzerland) · 2022Article
- Neurologic complications of coronavirus and other respiratory viral infections.Handbook of clinical neurology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewHeadache is a common symptom of COVID-19 with emerging literature being published on the subject. Although it may seem unspecific, scientific evidence has allowed a better definition of this headache type, revealing relevant associations with other COVID-19 symptoms and prognoses. We therefore sought to highlight the most remarkable findings concerning headache secondary to COVID-19, specifically focusing on epidemiology, characteristics, pathophysiology, and treatments. RECENT
findingsThe real prevalence of headache as a symptom of COVID-19 is still unclear ranging from 10 to 70%. Headache mainly has a tension-type-like phenotype, although 25% of individuals present with migraine-like features that also occur in patients without personal migraine history. This finding suggests that a likely pathophysiological mechanism is the activation of the trigeminovascular system. SARS-CoV-2 neurotropism can occur by trans-synaptic invasion through the olfactory route from the nasal cavity, leading to anosmia which has been associated with headache. SARS-CoV-2 protein has been found not only in olfactory mucosa and bulbs but also in trigeminal branches and the trigeminal ganglion, supporting this hypothesis. However, other mechanisms such as brain vessels inflammation due to SARS-CoV-2 damage to the endothelium or systemic inflammation in the context of cytokine storm cannot be ruled out. Interestingly, headache has been associated with lower COVID-19 mortality. No specific treatment for COVID-19 headache is available at present. Studies show that investigating COVID-19 headache represents an opportunity not only to better understand COVID-19 in general but also to advance in the knowledge of both secondary and primary headaches. Future research is therefore warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.